MicroRNA‐135a‐3p as a promising biomarker and nucleic acid therapeutic agent for ovarian cancer

Ovarian cancer is the most lethal gynecologic malignancy. Recently, several molecularly targeted anticancer agents have been developed for ovarian cancer; however, its prognosis remains extremely poor. The development of molecularly targeted therapy, as well as companion diagnostics, is required to...

Full description

Saved in:
Bibliographic Details
Published in:Cancer science 2017-05, Vol.108 (5), p.886-896
Main Authors: Fukagawa, Satoshi, Miyata, Kohei, Yotsumoto, Fusanori, Kiyoshima, Chihiro, Nam, Sung Ouk, Anan, Haruchika, Katsuda, Takahiro, Miyahara, Daisuke, Murata, Masaharu, Yagi, Hiroshi, Shirota, Kyoko, Yasunaga, Shin'ichiro, Kato, Kiyoko, Miyamoto, Shingo
Format: Article
Language:English
Subjects:
Animals
Antineoplastic Agents - therapeutic use
Antitumor agents
Biomarker
Biomarkers
Biomarkers, Tumor - genetics
Cancer therapies
Cell Line, Tumor
Cell proliferation
Cell Proliferation - drug effects
Cell Proliferation - genetics
Cisplatin
Cisplatin - therapeutic use
Cysts
Female
Gene Expression Profiling - methods
Gene Expression Regulation, Neoplastic - drug effects
Gene Expression Regulation, Neoplastic - genetics
Humans
Kinases
Malignancy
Mice
MicroRNAs
MicroRNAs - genetics
Middle Aged
miRNA
miR‐135a‐3p
molecular target
nucleic acid therapy
Original
Ovarian cancer
Ovarian Neoplasms - drug therapy
Ovarian Neoplasms - genetics
Paclitaxel
Paclitaxel - therapeutic use
Prognosis
Xenografts
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Ovarian cancer is the most lethal gynecologic malignancy. Recently, several molecularly targeted anticancer agents have been developed for ovarian cancer; however, its prognosis remains extremely poor. The development of molecularly targeted therapy, as well as companion diagnostics, is required to improve outcomes for patients with ovarian cancer. In this study, to identify microRNAs (miRNAs) involved in the progression of ovarian cancer we analyzed serum miRNAs in patients with ovarian cancer using miRNA array and quantitative RT‐PCR and examined the anticancer properties of miRNA expression in ovarian cancer cells. In patients with ovarian cancer, high amount of miR‐135a‐3p in serum samples was significantly associated with favorable clinical prognosis. The amount of miR‐135a‐3p was significantly decreased in patients with ovarian cancer compared with patients with ovarian cysts or normal ovaries. In SKOV‐3 and ES‐2 human ovarian cancer cells, enhanced expression of miR‐135a‐3p induced drug sensitivity to cisplatin and paclitaxel and suppressed cell proliferation and xenograft tumor growth. These findings suggest that miR‐135a‐3p may be considered as a biomarker and a therapeutic agent in ovarian cancer. lmiR‐135a‐3p serum expression is significantly involved in ovarian cancer prognosis. lmiR‐135a‐3p blocks ovarian cancer progression by suppressing oncogenic molecules. lmiR‐135a‐3p is useful both for ovarian cancer companion diagnostics and therapy.
ISSN:1347-9032
1349-7006
DOI:10.1111/cas.13210